Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey

Background  Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2013-01, Vol.27 (1), p.e8-e16
Hauptverfasser: Weller, K., Schoepke, N., Krause, K., Ardelean, E., Bräutigam, M., Maurer, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e16
container_issue 1
container_start_page e8
container_title Journal of the European Academy of Dermatology and Venereology
container_volume 27
creator Weller, K.
Schoepke, N.
Krause, K.
Ardelean, E.
Bräutigam, M.
Maurer, M.
description Background  Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. Objective  To analyse the management of urticaria patients in tertiary referral centres. Methods  During a standardized expert‐to‐expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticaria patient care with a special focus on csU. Results  On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non‐sedating H1‐antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine‐resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow‐up visits was reported to be above average in case of csU. Conclusion  This study indicates that some urticaria patients, especially those with unknown causes or with an H1‐antihistamine‐resistant disease, may benefit from a referral to tertiary care centres.
doi_str_mv 10.1111/j.1468-3083.2011.04387.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273270688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273270688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4077-6e43a49ad6b88c7c96bc03fd5808e438160ca89c070877c47971a62460dc0b383</originalsourceid><addsrcrecordid>eNqNkE1P3DAQhi3UChbav1D52EvC2M7648ABQctHUVFVWo6W40ykbLObre3A7r_HYeme64tHmueZ0byEUAYly-90UbJK6kKAFiUHxkqohFbl5oDM9o13ZAaGy8KYuTkixzEuADI614fkiHOmJAeYkcVP7NEnbOgYUudd6Bxdu9ThKkVa4wrbLtE2DEvqaMAWQ3A9TQNNmHEXtjQrSH3GA0ZaZCaOfVaHlroVxc06czSO4Qm3H8j71vURP779J-TX1y8PF9fF3f3VzcX5XeErUKqQWAlXGdfIWmuvvJG1B9E2cw06tzST4J02HhRopXyljGJO8kpC46EWWpyQz7u56zD8HTEmu-yix753KxzGaBlXgiuQekL1DvVhiDHfZ9ehW-azLAM7JW0XdgrUToHaKWn7mrTdZPXT25axXmKzF_9Fm4GzHfDc9bj978H29vL3VGW_2PldTLjZ-y78sVIJNbeP36-s4Q_fHn9c5kK8AGbpm9w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273270688</pqid></control><display><type>article</type><title>Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Weller, K. ; Schoepke, N. ; Krause, K. ; Ardelean, E. ; Bräutigam, M. ; Maurer, M.</creator><creatorcontrib>Weller, K. ; Schoepke, N. ; Krause, K. ; Ardelean, E. ; Bräutigam, M. ; Maurer, M.</creatorcontrib><description>Background  Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. Objective  To analyse the management of urticaria patients in tertiary referral centres. Methods  During a standardized expert‐to‐expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticaria patient care with a special focus on csU. Results  On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non‐sedating H1‐antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine‐resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow‐up visits was reported to be above average in case of csU. Conclusion  This study indicates that some urticaria patients, especially those with unknown causes or with an H1‐antihistamine‐resistant disease, may benefit from a referral to tertiary care centres.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/j.1468-3083.2011.04387.x</identifier><identifier>PMID: 22176200</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Chronic Disease ; Cyclosporine - therapeutic use ; Dermatology - standards ; Dermatology - trends ; Female ; Germany ; Health Care Surveys ; Histamine Antagonists - therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Patient Selection ; Prognosis ; Referral and Consultation - statistics &amp; numerical data ; Risk Assessment ; Surveys and Questionnaires ; Tertiary Care Centers ; Treatment Outcome ; Urticaria - diagnosis ; Urticaria - drug therapy ; Urticaria - epidemiology</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2013-01, Vol.27 (1), p.e8-e16</ispartof><rights>2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology</rights><rights>2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4077-6e43a49ad6b88c7c96bc03fd5808e438160ca89c070877c47971a62460dc0b383</citedby><cites>FETCH-LOGICAL-c4077-6e43a49ad6b88c7c96bc03fd5808e438160ca89c070877c47971a62460dc0b383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-3083.2011.04387.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-3083.2011.04387.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22176200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weller, K.</creatorcontrib><creatorcontrib>Schoepke, N.</creatorcontrib><creatorcontrib>Krause, K.</creatorcontrib><creatorcontrib>Ardelean, E.</creatorcontrib><creatorcontrib>Bräutigam, M.</creatorcontrib><creatorcontrib>Maurer, M.</creatorcontrib><title>Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background  Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. Objective  To analyse the management of urticaria patients in tertiary referral centres. Methods  During a standardized expert‐to‐expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticaria patient care with a special focus on csU. Results  On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non‐sedating H1‐antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine‐resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow‐up visits was reported to be above average in case of csU. Conclusion  This study indicates that some urticaria patients, especially those with unknown causes or with an H1‐antihistamine‐resistant disease, may benefit from a referral to tertiary care centres.</description><subject>Adult</subject><subject>Aged</subject><subject>Chronic Disease</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dermatology - standards</subject><subject>Dermatology - trends</subject><subject>Female</subject><subject>Germany</subject><subject>Health Care Surveys</subject><subject>Histamine Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Selection</subject><subject>Prognosis</subject><subject>Referral and Consultation - statistics &amp; numerical data</subject><subject>Risk Assessment</subject><subject>Surveys and Questionnaires</subject><subject>Tertiary Care Centers</subject><subject>Treatment Outcome</subject><subject>Urticaria - diagnosis</subject><subject>Urticaria - drug therapy</subject><subject>Urticaria - epidemiology</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1P3DAQhi3UChbav1D52EvC2M7648ABQctHUVFVWo6W40ykbLObre3A7r_HYeme64tHmueZ0byEUAYly-90UbJK6kKAFiUHxkqohFbl5oDM9o13ZAaGy8KYuTkixzEuADI614fkiHOmJAeYkcVP7NEnbOgYUudd6Bxdu9ThKkVa4wrbLtE2DEvqaMAWQ3A9TQNNmHEXtjQrSH3GA0ZaZCaOfVaHlroVxc06czSO4Qm3H8j71vURP779J-TX1y8PF9fF3f3VzcX5XeErUKqQWAlXGdfIWmuvvJG1B9E2cw06tzST4J02HhRopXyljGJO8kpC46EWWpyQz7u56zD8HTEmu-yix753KxzGaBlXgiuQekL1DvVhiDHfZ9ehW-azLAM7JW0XdgrUToHaKWn7mrTdZPXT25axXmKzF_9Fm4GzHfDc9bj978H29vL3VGW_2PldTLjZ-y78sVIJNbeP36-s4Q_fHn9c5kK8AGbpm9w</recordid><startdate>201301</startdate><enddate>201301</enddate><creator>Weller, K.</creator><creator>Schoepke, N.</creator><creator>Krause, K.</creator><creator>Ardelean, E.</creator><creator>Bräutigam, M.</creator><creator>Maurer, M.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201301</creationdate><title>Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey</title><author>Weller, K. ; Schoepke, N. ; Krause, K. ; Ardelean, E. ; Bräutigam, M. ; Maurer, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4077-6e43a49ad6b88c7c96bc03fd5808e438160ca89c070877c47971a62460dc0b383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Chronic Disease</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dermatology - standards</topic><topic>Dermatology - trends</topic><topic>Female</topic><topic>Germany</topic><topic>Health Care Surveys</topic><topic>Histamine Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Selection</topic><topic>Prognosis</topic><topic>Referral and Consultation - statistics &amp; numerical data</topic><topic>Risk Assessment</topic><topic>Surveys and Questionnaires</topic><topic>Tertiary Care Centers</topic><topic>Treatment Outcome</topic><topic>Urticaria - diagnosis</topic><topic>Urticaria - drug therapy</topic><topic>Urticaria - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weller, K.</creatorcontrib><creatorcontrib>Schoepke, N.</creatorcontrib><creatorcontrib>Krause, K.</creatorcontrib><creatorcontrib>Ardelean, E.</creatorcontrib><creatorcontrib>Bräutigam, M.</creatorcontrib><creatorcontrib>Maurer, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weller, K.</au><au>Schoepke, N.</au><au>Krause, K.</au><au>Ardelean, E.</au><au>Bräutigam, M.</au><au>Maurer, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2013-01</date><risdate>2013</risdate><volume>27</volume><issue>1</issue><spage>e8</spage><epage>e16</epage><pages>e8-e16</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background  Urticaria is a frequent reason for consultations. Recently, it has been demonstrated that the management of chronic spontaneous urticaria (csU) in the practice setting does not fully comply with published guidelines. In addition, it was shown that one of four csU patients is referred to specialized centres. Objective  To analyse the management of urticaria patients in tertiary referral centres. Methods  During a standardized expert‐to‐expert interview, 41 specialists from German tertiary care centres were asked for different aspects of urticaria patient care with a special focus on csU. Results  On average, the participating centres saw 25 csU patients per month. All ran programmes for the identification of underlying causes with an average success rate of 45 ± 3% which is considerably higher as has been found in the practice setting. In those patients where an identification succeeds, infections, drugs, intolerance and autoreactivity were reported to be causes in 41%, 20%, 17% and 16%. In their symptomatic treatment the majority of centres (71%) followed the guidelines by using regular dosed non‐sedating H1‐antihistamines as first line and higher doses (61%) as second line option. In contrast to the practice setting, meaningful experience also existed for alternative therapies in antihistamine‐resistant patients, such as dapsone, cyclosporin and omalizumab. The expenditure of time, laboratory costs and frequency of follow‐up visits was reported to be above average in case of csU. Conclusion  This study indicates that some urticaria patients, especially those with unknown causes or with an H1‐antihistamine‐resistant disease, may benefit from a referral to tertiary care centres.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22176200</pmid><doi>10.1111/j.1468-3083.2011.04387.x</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2013-01, Vol.27 (1), p.e8-e16
issn 0926-9959
1468-3083
language eng
recordid cdi_proquest_miscellaneous_1273270688
source MEDLINE; Wiley Online Library All Journals
subjects Adult
Aged
Chronic Disease
Cyclosporine - therapeutic use
Dermatology - standards
Dermatology - trends
Female
Germany
Health Care Surveys
Histamine Antagonists - therapeutic use
Humans
Incidence
Male
Middle Aged
Patient Selection
Prognosis
Referral and Consultation - statistics & numerical data
Risk Assessment
Surveys and Questionnaires
Tertiary Care Centers
Treatment Outcome
Urticaria - diagnosis
Urticaria - drug therapy
Urticaria - epidemiology
title Selected urticaria patients benefit from a referral to tertiary care centres - results of an expert survey
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T06%3A10%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selected%20urticaria%20patients%20benefit%20from%20a%20referral%20to%20tertiary%20care%20centres%20-%20results%20of%20an%20expert%20survey&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Weller,%20K.&rft.date=2013-01&rft.volume=27&rft.issue=1&rft.spage=e8&rft.epage=e16&rft.pages=e8-e16&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/j.1468-3083.2011.04387.x&rft_dat=%3Cproquest_cross%3E1273270688%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273270688&rft_id=info:pmid/22176200&rfr_iscdi=true